Log in with your email address username.


[Correspondence] Beyond ESPAC-4: better surgery and systemic therapy

We appreciate the commentary on our Article (March 11, p 1011)1 by Gaël Deplanque and Nicolas Demartines (March 11, p 985)2 concluding that the ESPAC-4 trial “…clearly establishes the combination of gemcitabine and capecitabine as a new standard of care in the adjuvant setting of pancreatic ductal adenocarcinoma”.